Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Recommendation of “Moderate Buy” by Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $50.30.

CAPR has been the subject of several recent analyst reports. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Roth Mkm reissued a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a research note on Friday, May 15th. Finally, B. Riley Financial increased their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th.

Insider Activity

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the completion of the sale, the chief financial officer owned 8,223 shares in the company, valued at $260,669.10. This represents a 75.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the sale, the director owned 7,529 shares of the company’s stock, valued at approximately $240,928. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 173,429 shares of company stock valued at $5,329,440. Company insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its holdings in shares of Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 2,786 shares in the last quarter. ACT Capital Management LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth $43,000. KBC Group NV purchased a new stake in shares of Capricor Therapeutics during the first quarter worth $44,000. GoalVest Advisory LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth $59,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 4,976 shares in the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Price Performance

CAPR opened at $26.44 on Monday. The firm has a market cap of $1.53 billion, a PE ratio of -11.40 and a beta of 0.39. The business has a fifty day simple moving average of $30.00 and a 200-day simple moving average of $28.41. Capricor Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities research analysts anticipate that Capricor Therapeutics will post -0.49 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.